EpiCypher (Durham, NC) and New England Biolabs (Ipswich, MA) announced an expanded strategic partnership on covering co-development of next-generation epigenomics research tools and the international distribution of EpiCypher’s CUTANA product portfolio. Under the agreement, NEB will initially distribute CUTANA products in Germany and the United Kingdom, with additional markets expected to follow later in 2026. Financial terms were not disclosed.
The collaboration centers on EpiCypher’s CUTANA platform, which covers CUT&RUN, CUT&Tag, Fiber-seq, and DNA methylation profiling assays, alongside the CUTANA Cloud bioinformatics platform and a portfolio of designer nucleosomes. NEB contributes its Enzymatic Methyl-seq (EM-seq) technology and broader NGS enzyme and reagent capabilities. Jointly developed products already in the market include solutions for CUT&RUN, CUT&Tag, and NiCE-seq workflows, as well as multiomic applications such as Multiomic CUT&RUN and meCUT&RUN. EpiCypher’s recently launched CUTANA Fiber-seq kit integrates NEB reagents that the companies said helped accelerate the product’s path to market. Some jointly developed tools have received partial support from NIH Small Business Innovation Research funding.
NEB will serve as distributor for EpiCypher’s CUTANA genomics product portfolio in key international markets, beginning with Germany and the United Kingdom. The companies indicated that additional markets will be added later in 2026, though no further territorial detail was disclosed. No upfront payment, milestone structure, royalty terms, equity investment, or aggregate deal value was referenced in the announcement. Both companies remain privately held.
Deal context and prior epigenomics collaboration
The expanded agreement builds on an earlier EpiCypher–NEB collaboration that produced jointly developed chromatin analysis tools and library preparation products. EpiCypher has been an active dealmaker in the epigenomics collaboration space: in January 2024, the company partnered with AtlasXomics to develop CUT&Tag kits and assay services for spatial epigenomics applications, and in September 2024, it expanded an exclusive licensing agreement with Fred Hutch Cancer Center covering intellectual property underlying CUT&Tag technology. NEB entered a separate co-development arrangement with French biotech Inorevia in June 2024 to build automated NGS library preparation workflows integrating NEBNext reagents with Inorevia’s Magelia automation platform.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/